Randomized, Double Blind,Placebo-Controlled, Multicenter Study Evaluating the Safety and Pharmacokinetics of Different Dosing Regimens of Favipiravir in Healthy Adult Subjects and Adult Subjects With Uncomplicated Influenza
Phase of Trial: Phase I/II
Latest Information Update: 24 Oct 2015
At a glance
- Drugs Favipiravir (Primary)
- Indications Influenza virus infections
- Focus Pharmacokinetics
- Acronyms FAVOR
- Sponsors FUJIFILM Pharma; MDVI
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jan 2013 Planned number of patients changed from 450 to 550 as reported by ClinicalTrials.gov.
- 22 Jan 2013 Planned number of patients changed from 228 to 450 as reported by ClinicalTrials.gov.